Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295862019> ?p ?o ?g. }
Showing items 1 to 51 of
51
with 100 items per page.
- W4295862019 endingPage "65" @default.
- W4295862019 startingPage "56" @default.
- W4295862019 abstract "Introduction. Prostate cancer (PC), according to the results for 2019, is the second most frequently diagnosed malignant tumor in men living in the Russian Federation. There is a significant proportion of patients with advanced (III-IV stages) of prostate cancer - up to 50 %, while metastatic cancer accounts for up to 18.1 % of patients. Popularization in the Moscow City Healthcare clinical practice of innovative technologies for managing patients with metastatic castration-resistant prostate cancer (mCRPC) directly meets the goals and objectives of the Federal project aimed at increasing the life expectancy of cancer patients.
 Materials and methods. The article reviews the results of clinical developments in the field of mCRPC treatment presented at The ASCO Annual Meeting, June 3-7, 2022: VISION sub-studies, TheraP study, study of the prognostic role of circulating tumor DNA (ctDNA) in the early choice of a strategy for the use of abiraterone or enzalutamide in patients with initial mCRPC - treatment naïve - status.
 Results and discussion. The volume of clinical information on the results of theranostic antitumor radiation technologies implemented with the participation of prostate-specific membrane antigen (hereinafter referred to as PSMA) is growing rapidly. PSMA - mediated radio-imaging is considered as a potentially effective tool for selecting patients who are sensitive to specific therapy. When studying radionuclide therapy mediated by a ligand to PSMA (PSMA-L), the main efforts are focused on determining the optimal regimens for its clinical application. The possibility of expanding the current indications for prescribing 177Lu-PSMA-617 to patients with prostate cancer at an earlier stage is also being studied. Until final results are obtained from clinical trials that provide clear answers to open questions regarding various aspects of the application of innovative PSMA - mediated theranostic technologies, it remains very important to reach an expert consensus, within the framework of an exchange of opinions, re arding their appropriate use in various clinical situations." @default.
- W4295862019 created "2022-09-15" @default.
- W4295862019 creator A5036625312 @default.
- W4295862019 creator A5075376457 @default.
- W4295862019 date "2022-06-30" @default.
- W4295862019 modified "2023-10-14" @default.
- W4295862019 title "Analysis of innovative clinical developments in the field of therapy for metastatic prostate cancer: bright results of the ASCO Congress-2022" @default.
- W4295862019 doi "https://doi.org/10.47619/2713-2617.zm.2022.v.3i2;56-65" @default.
- W4295862019 hasPublicationYear "2022" @default.
- W4295862019 type Work @default.
- W4295862019 citedByCount "0" @default.
- W4295862019 crossrefType "journal-article" @default.
- W4295862019 hasAuthorship W4295862019A5036625312 @default.
- W4295862019 hasAuthorship W4295862019A5075376457 @default.
- W4295862019 hasBestOaLocation W42958620191 @default.
- W4295862019 hasConcept C121608353 @default.
- W4295862019 hasConcept C126322002 @default.
- W4295862019 hasConcept C143998085 @default.
- W4295862019 hasConcept C2776421732 @default.
- W4295862019 hasConcept C2776551883 @default.
- W4295862019 hasConcept C2780192828 @default.
- W4295862019 hasConcept C61367390 @default.
- W4295862019 hasConcept C71924100 @default.
- W4295862019 hasConceptScore W4295862019C121608353 @default.
- W4295862019 hasConceptScore W4295862019C126322002 @default.
- W4295862019 hasConceptScore W4295862019C143998085 @default.
- W4295862019 hasConceptScore W4295862019C2776421732 @default.
- W4295862019 hasConceptScore W4295862019C2776551883 @default.
- W4295862019 hasConceptScore W4295862019C2780192828 @default.
- W4295862019 hasConceptScore W4295862019C61367390 @default.
- W4295862019 hasConceptScore W4295862019C71924100 @default.
- W4295862019 hasIssue "2" @default.
- W4295862019 hasLocation W42958620191 @default.
- W4295862019 hasOpenAccess W4295862019 @default.
- W4295862019 hasPrimaryLocation W42958620191 @default.
- W4295862019 hasRelatedWork W122177069 @default.
- W4295862019 hasRelatedWork W2414042649 @default.
- W4295862019 hasRelatedWork W2584454163 @default.
- W4295862019 hasRelatedWork W2765333766 @default.
- W4295862019 hasRelatedWork W2783882412 @default.
- W4295862019 hasRelatedWork W2917061290 @default.
- W4295862019 hasRelatedWork W2942985299 @default.
- W4295862019 hasRelatedWork W2982156914 @default.
- W4295862019 hasRelatedWork W2996229517 @default.
- W4295862019 hasRelatedWork W3217365879 @default.
- W4295862019 hasVolume "3" @default.
- W4295862019 isParatext "false" @default.
- W4295862019 isRetracted "false" @default.
- W4295862019 workType "article" @default.